Curis Reports Q1 Net Loss of $24.2M, Zero Revenue; Projects Conditional Cash Runway into H2 2027 Amid Delisting Threat

summarizeSummary

Curis announced a Q1 2026 net loss of $24.2 million and no revenue, with cash and equivalents of $15.0 million, projecting a conditional cash runway into H2 2027 based on future warrant exercises.

check_boxKey Events

• Significant Net Loss Reported

  Curis reported a net loss of $24.2 million for the first quarter of 2026, a substantial increase from $10.6 million in the same period last year. This quarterly loss significantly exceeds the company's current market capitalization.

• Zero Revenue in Q1 2026

  The company recorded no revenue for Q1 2026, down from $2.4 million in Q1 2025, primarily due to the sale of Erivedge® royalties in Q4 2025.

• Conditional Cash Runway Guidance

  Curis projects its cash and cash equivalents of $15.0 million as of March 31, 2026, combined with an anticipated $20.2 million from the exercise of Series B warrants (contingent on a clinical milestone), should fund operations into the second half of 2027.

• Increased Other Expenses

  Other expense, net, increased significantly to $12.7 million in Q1 2026, primarily due to a change in the fair value of the warrant liability associated with the January 2026 PIPE Financing.

auto_awesomeAnalysis

Curis reported a substantial net loss for Q1 2026 that exceeds its current market capitalization, coupled with zero revenue, highlighting severe financial distress. While the company projects a cash runway into the second half of 2027, this is conditional on the exercise of Series B warrants, which are currently out-of-the-money and dependent on a clinical milestone. This update reinforces the 'going concern' warning from the prior 10-K and provides critical context following the recent Nasdaq delisting notice, indicating a highly precarious financial situation.